{"commentary":{"count":138,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":133,"youtube":4,"podcast":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04071457\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"DRAMMATIC","nct_id":"NCT04071457","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=drammatic-nct04071457. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"DRAMMATIC","arms":[{"description":"Study entry/screening to follow patient until Maintenance.","label":"Study Entry / Screening","type":"NO_INTERVENTION"},{"description":"Lenalidomide 10 mg/day, D1-28, q28 days for 3 cycles, then 15 mg/day, D1-28 for up to 2 years from starting treatment.","label":"Arm 1: Lenalidomide","type":"ACTIVE_COMPARATOR"},{"description":"Lenalidomide 10 mg/day, D1-28, q28 days for 3 cycles, then 15 mg/day, D1-28 for up to 2 years from starting treatment. Plus Daratumumab/rHuPH20 1800 mg/30,000 units D1, 8, 15, 22 q 28 days for 2 cycles, then D 1 and 15 q 28 days for cycles 3-6 then D1 q 28 days for subsequent cycles for up to 2 years from starting treatment.","label":"Arm 2: Lenalidomide + Daratumumab/rHuPH20","type":"EXPERIMENTAL"},{"description":"MRD+ or MRD- and randomized to Arm 1a: Lenalidomide 10 mg/day, D1-28, q28 days for 3 cycles, then 15 mg/day, D1-28 for up to 7 years from starting treatment.","label":"Arm 1a: Continue Lenalidomide","type":"ACTIVE_COMPARATOR"},{"description":"MRD- and randomized to Arm 1b: Discontinue protocol therapy.","label":"Arm 1b: Stop Lenalidomide","type":"NO_INTERVENTION"},{"description":"MRD+ or MRD- and randomized to Arm 2a: Lenalidomide 10 mg/day, D1-28, q28 days for 3 cycles, then 15 mg/day, D1-28 for up to 7 years from starting treatment. Plus Daratumumab/rHuPH20 1800 mg/30,000 units D1, 8, 15, 22 q 28 days for 2 cycles, then D 1 and 15 q 28 days for cycles 3-6 then D1 q 28 days for subsequent cycles for up to 7 years from starting treatment.","label":"Arm 2a: Continue Lenalidomide + Daratumumab/rHuPH20","type":"ACTIVE_COMPARATOR"},{"description":"MRD- and randomized to Arm 2b: Discontinue protocol therapy.","label":"Arm 2b: Stop Lenalidomide + Daratumumab/rHuPH20","type":"NO_INTERVENTION"}],"collaborators":["National Cancer Institute (NCI)","Janssen, LP"],"completion_date":{"date":"2040-07-01","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":1100,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Lenalidomide","type":"DRUG"},{"name":"Daratumumab/rHuPH20","type":"DRUG"}],"last_update":"2026-09-17","lead_sponsor":"SWOG Cancer Research Network","official_title":"S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2032-09","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival","timeFrame":"From date of intial randomization until death due to any cause, assessed up to 15 years"}],"references":[{"citation":"Swan D, Henderson R, McEllistrim C, Naicker SD, Quinn J, Cahill MR, Mykytiv V, Lenihan E, Mulvaney E, Nolan M, Parker I, Natoni A, Lynch K, Ryan AE, Szegezdi E, Krawczyk J, Murphy P, O'Dwyer M. CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment. Clin Lymphoma Myeloma Leuk. 2022 Nov;22(11):847-852. doi: 10.1016/j.clml.2022.07.011. Epub 2022 Jul 21.","pmid":"35985959","type":"DERIVED"}],"start_date":{"date":"2019-08-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration","url":"https://clinicaltrials.gov/study/NCT04071457"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/drammatic-nct04071457"}